Cyramza 500mg is a type of Intravenous human monoclonal antibody which prohibits VEGFR2.
Cyramza 500mg Increased risk of haemorrhage that may be severe and sometimes fatal. Discontinue if severe bleeding occurs.
Cyramza 500mg is a prescription drugs which is used under supervision of doctor.
Cyramza 500mg injection indicated for :
The treatment of advanced or metastatic gastric or gastroesophageal junction adenocarcinoma - As a single agentor in combination with paclitaxel
The treatment for metastatic non-small cell lung cancer - In combination with docetaxel
The treatment of patients with metastatic colorectal cancer -In combination with FOLFIRI.
Mechanism of action
Ramucirumab belongs to human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), which is a type II trans-membrane tyrosine kinase receptor show on endothelial cells. By binding to VEGFR2, ramucirumab inhibits binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), hence prohibiting VEGF-stimulated receptor phosphorylation and downstream ligand-induced multiplication, permeability, and migration of human endothelial cells.
Half-life of ramucirumab 14 days
Non-Small Cell Lung Cancer :
The recommended dose is 10 mg/kg IV infused over ~1 hr prior to docetaxel (75 mg/m²) IV infusion on Day 1 of a 21-day cycle
Gastric Cancer :
As a monotherapy agent or in co administration with paclitaxel is used.
Recommended dose for Single agent or in combination with paclitaxel is 8 mg/kg IV q2wk; infuse over 1 hr
Recommended dose for Paclitaxel (if given in combination) is 80 mg/m² once weekly for 3 weeks of every 28-day cycle.
When given in concomitant, administer ramucirumab prior to administration of paclitaxel
Colorectal Cancer :
In combination with FOLFIRI for the treatment
Recommended dose is 8 mg/kg IV q2wk; administer by IV infusion over 60 minutes prior to FOLFIRI administration
Cyramza 500mg have side effects for gastric cancer with combination of paclitaxel :
• Peripheral edema
• Infusion-related reactions
• Hypertension grade 3-4
• Hypoalbuminemia .
Cyramza 500mg have side effects for non-small cell lung cancer
• Stomatitis/mucosal inflammation
• Febrile neutropenia
• Peripheral edema
• Lacrimation increased
Can have high the risk of gastrointestinal perforation, a probably fatal event
Completely discontinue in patients who experience a gastrointestinal perforation
Impaired wound healing can appear with antibodies prohibiting the VEGF pathway
Stop in patients with impaired wound healing
Hold up drug prior to surgery and discontinue if a patient occurs wound healing complications
Have high the risk of haemorrhage and gastrointestinal haemorrhage, containingserious and sometimes fatal haemorrhagic events enduringly discontinue patients who experience severe bleeding